Ignite Creation Date:
2024-10-25 @ 8:04 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06643728
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-14
Brief Title:
A Study to Investigate Weight Management With Bimagrumab LY3985863 and Tirzepatide LY3298176 Alone or in Combination in Adults With Obesity or Overweight
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase 2 Double-Blind Randomized Placebo-Controlled Study of Bimagrumab and Tirzepatide Alone or in Combination to Investigate the Efficacy and Safety in Adult Participants With Obesity or Overweight Without Type 2 Diabetes
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide alone or in combination in adults with obesity or overweight with at least one obesity related comorbidity without Type 2 Diabetes The study will last about 54 weeks
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None